Several factors – including age, disease location, concomitant IBD-associated spondyloarthropathy, calprotectin levels – may influence the response to anti-TNF-α therapy.
Abstract
Introduction Reliable biomarkers are needed to predict response to anti-TNF-α therapy in patients with inflammatory bowel disease. Aim The primary aim of this study was to evaluate the usefulness of serum oncostatin M (OSM) as a marker of response to anti-TNF-α therapy in patients with inflammatory bowel disease (IBD). A secondary endpoint was the identification of additional factors that may influence the response to anti-TNF-α treatment. Material and methods The study included 135 patients treated with infliximab or adalimumab. Serum OSM and faecal calprotectin levels were measured at baseline and after 14 weeks of therapy. Results Baseline OSM levels were significantly lower in responders than in non-responders (MD = −348.07; 95% CI: –400.72 to –242.96; p < 0.001) and demonstrated high accuracy in predicting treatment outcomes (AUC = 0.908; 95% CI: 0.848–0.960; p < 0.001). Patients with baseline OSM concentrations below 216.82 pg/ml were more likely to respond to therapy, with a sensitivity of 92% and a specificity of 77%. Baseline faecal calprotectin levels showed low-to-moderate predictive value for treatment response (AUC = 0.690; 95% CI: 0.589–0.780; p = 0.005). A significant difference in treatment response was observed with respect to prior exposure to biologic therapy (23.9% vs. 69.8%; p < 0.001), with a moderate association strength as measured by Cramér’s V (V = 0.44; 95% CI: 0.28–0.59). Conclusions Several factors – including age, disease location, concomitant IBD-associated spondyloarthropathy, calprotectin levels – may influence the response to anti-TNF-α therapy. However, only low serum OSM concentration was consistently associated with a better treatment response and may represent a promising biomarker and potential therapeutic target in IBD.
Anti-tumor necrosis factor-α (anti-TNF-α) agents are a cornerstone in inflammatory bowel disease (IBD) therapy, yet primary non-response remains a significant practical challenge. Leucine-rich alpha-2 glycoprotein (LRG) has been recognized as a promising marker for disease activity. This study aimed to evaluate the pre...
Ibrahim Amer, H. El Batae, Yasmin A. Elshaer et al.· BMC Gastroenterology· 0 citations
Background Serum leucine-rich α2-glycoprotein1 (LRG1) is a promising biomarker for mucosal inflammation in ulcerative colitis (UC). However, because systemic LRG1 expression is partly tumor necrosis factor-α (TNF-α)-dependent, anti-TNF therapy may pharmacologically suppress its levels independently of mucosal status. O...
Akihiro Dejima, H. Takatori, Masaki Miyazawa et al.· Therapeutic Advances in Gast...· 0 citations
IL12B rs6887695 emerged as a potential pharmacogenetic marker associated with favorable ustekinumab outcomes; however, this exploratory and hypothesis-generating finding requires external validation in larger, independent cohorts before clinical application.
Ylenia Marino, M. Rottura, Claudia Ligresti et al.· Pharmaceuticals· 0 citations
Background: This study evaluated the clinical value of ackground:
combined serum tumor necrosis factor-a (TNF-a), interleukin-10 (IL-10), and fecal calprotectin (FC) measurements for assessing inflammatory bowel disease (IBD)
activity and supporting individualized management.
Methods: In this retrospective comparative...
Dan-Qian Meng, Fan Yang· Journal of Medical Biochemis...· 0 citations
Serum miR-7641 was downregulated in RA patients and identified as an independent protective factor with high diagnostic accuracy and exerts protective effects by targeting TNFSF10 to inhibit proliferation and inflammation in an immortalized synovial cell model.
Yu-Chen Zhang, Huijie Chen, Hong-Ming Liang et al.· International Journal of Imm...· 0 citations
Introduction
. Psoriasis is a common chronic immune-mediated inflammatory skin disease that significantly reduces patients’ quality of life. Modern treatment approaches, especially biologic therapy, demonstrate high efficacy; however, there is substantial interpatient variability in treatment response.
Aim
. T...
A. A. Arsenyeva, A. Ereshchenko, A. V. Lyamin et al.· Meditsinskiy sovet = Medical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.